

9th August 2017

Respiri remains on track for commercialisation

In response to shareholder enquiries, the directors of Respiri would like to re-affirm that the company's asthma symptom management solution remains on track for commercialisation.

The recently released high profile test study results from a medical development company will have no impact on Respiri's product development and commercialisation.

The Respiri digital wheeze detection solution includes a breath sensor, technology platform, leading edge algorithm and consumer app. Respiri's global clinical studies and research confirm its capability to measure wheeze – the major symptom of asthma.

The final step of commercialisation is replacing the 2013 AirSonea breath sensor with a 2018 next generation device. This ensures the compatibility between the breath sensor and Respiri's recently launched software platform.

Respiri is pleased with the progress during its three-year development phase in successfully finalising the clinically validated platform. From the end of 2014, the key steps have included moving the algorithm from the cloud inside the mobile platform, then combining the algorithm to detect breath, remove ambient sounds and analyse the wheeze rate.

Respiri strategically decided that the microphone detecting the wheeze should be a separate handheld breath sensor device rather than relying on the ever changing technology of multiple smartphone makers. This ensures data integrity and a more comfortable consumer experience.

Respiri provides an important self-management tool for diagnosed asthmatics and doesn't attempt to diagnose asthma in competition with doctors, radiologists and pathologists.

As announced on the 27th of July, Respiri's breath sensor development will take a minimum of six months, and combine with the software app that is already finalised. Respiri is focused on a measured approach to the development of new technology, to maximise shareholder value creation opportunities.

Leon L'Huillier
Chairman
Ph: 1800 476 632

About Respi Limited

Respi Limited (ASX:RSH) is a medical technology company leading the way in the development of innovative devices and mobile health apps to improve the management of chronic and costly respiratory disorders such as asthma and COPD. Building on decades of experience in the research and development of cutting-edge clinical products for hospitals, the company has first-mover advantage in providing broad access to its proprietary acoustic based clinical solutions for remote monitoring with the development of a suite of over-the-counter connected devices. Health authorities universally agree that mHealth solutions can transform asthma care and health conscious consumers are rapidly embracing patient self-management with the aid of smartphones, the growth engine for Respi's flagship product, AirSonea®. With the addition of new products, including a connected device for nocturnal monitoring in development, Respi has a captive market, globally, of parents and carers of young children who cannot perform lung function tests. Respi products have been cleared for use by the US Food and Drug Administration, the European Union CE, the Australian TGA and the commencement of an approval process for Asian markets has begun.